Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266.SS) SHH
95.90
-0.36(-0.37%)
Currency In CNY
- General
- Statistics
- Historical Data
- Profile
- Financials
95.90
-0.36(-0.37%)
Currency In CNY
Sector
Healthcare
Industry
Biotechnology
Employees
867
First IPO Date
January 23, 2020
| Name | Title | Pay | Year Born |
| Zeqi Sheng | Chief Scientific Officer | 0 | 1964 |
| Binhua Lyu | Deputy GM, EVice President of Chemistry & Director | 0 | 1979 |
| Jisheng Wu | Director & Deputy GM | 0 | 1965 |
| Zelin Sheng | Chairman of the Board & GM | 0 | 1960 |
| Shice Shao | Accounting Supervisor | 0 | N/A |
| Gang Huang | Chief Financial Officer & Deputy GM | 0 | 1971 |
| Huiping Lu | Executive Vice President & Director | 0 | 1967 |
| Qingping Gao | Deputy GM & Board Secretary | 0 | 1977 |
Suzhou Zelgen Biopharmaceuticals Co., Ltd. researches and develops, manufactures, and sells medicines in the People's Republic of China. It offers small molecule and recombinant protein drugs for the treatment of liver cancer, non-small cell lung cancer, colorectal cancer, thyroid cancer, nasopharyngeal carcinomas, myelofibrosis, hemorrhage, and hepatobiliary diseases. The company was founded in 2009 and is based in Kunshan, the People's Republic of China.